Related Experiment Video
Updated: May 20, 2025

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
Published on: June 18, 2020
Simultaneous estimation of bioactive markers using validated HPTLC method and assessment of hepatoprotective effect
Dipal M Gandhi1, Kriti H Sharma2, Aakash Kumar S3
1Department of Pharmacognosy, Institute of Pharmacy, Nirma University, Ahmedabad 382481, Gujarat, India.
Abstract:
A new, precise, and reproducible HPTLC method was developed and validated for the estimation of andrographolide (AG), gallic acid (GA), and kutkin (KT2) in an ayurvedic formulation, HEPASAVE Syrup. The quantification of the three biomarkers was performed on TLC aluminum plates pre-coated with silica gel 60F254 as stationary phase. Linear ascending development was carried out in a Camag twin trough glass chamber saturated with toluene: ethyl acetate: formic acid: methanol (3:3:0.8:0.4, v/v/v/v) at room temperature (25 ± 2 °C). Camag TLC scanner III was used for simultaneous spectro-densitometric scanning and analysis in absorbance mode at 254 nm. The system was found to give compact spots for AG, GA, and KT2 with the respective Rf values of 0.74, 0.66, and 0.21. The data for calibration plots showed a good linear relationship for AG with r2 = 0.995, GA with r2 = 0.993, and KT2 with r2 = 0.992 in the concentration range of 200 ng to 800 ng, 80 ng to 320 ng and 2000 ng to 6000 ng, respectively to the peak area. The amount of AG, GA, and KT2 in the formulation was quantified and found to be 1.27 %w/v, 1.15 %w/v, and 0.014 %w/v, respectively. Statistical analysis of the data showed that the method is reproducible for the quantification of AG, GA, and KT2, simultaneously in HEPASAVE Syrup. It also significantly reduced the levels of SGPT, SGOT, and ALP in animals.
More Related Videos
Related Concept Videos
Hepatic Drug Clearance: Effect of Protein Binding
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion,...

